FDA Inspection 1277224 — Daiichi Sankyo, Inc.
The FDA completed an inspection of Daiichi Sankyo, Inc. on August 1, 2025 in Basking Ridge, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 2 citations were issued during this inspection. Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- August 1, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Basking Ridge, NJ (United States)
Additional Details
Risk Evaluation and Mitigation Strategies (REMS)
Citations
| ID | CFR | Description |
|---|---|---|
| 21354 | FDCA 505-1(f)(3)(A) | Failure to comply with REMS Elements to Assure Safe Use (ETASU) A |
| 21360 | FDCA 505-1(f)(4) | Failure to comply with REMS Implementation System |